Aurobindo Pharma's net profit rises 4.6% at Rs 639.5 crore in Q2, revenues grow nearly 18%
5 years, 2 months ago

Aurobindo Pharma's net profit rises 4.6% at Rs 639.5 crore in Q2, revenues grow nearly 18%

Firstpost  

Formulation revenues for the quarter posted a growth of 21.8% YoY to Rs 4,793.8 crore and accounted for 85.6% of total revenues. Hyderabad: Aurobindo Pharma Limited on Tuesday said its consolidated net profit for the quarter ended 30 September was up by 4.6 percent to Rs 639.5 crore against Rs 611.4 crore in the Q2 FY 19. Revenues from operation grew by nearly 18 percent to Rs 5600.5 crore. Our R&D initiatives have been progressing well across the products basket and we have started clinical trials for our first biosimilar product in Q3 FY 20.” Formulation revenues for the quarter posted a growth of 21.8 percent YoY to Rs 4,793.8 crore and accounted for 85.6 percent of total revenues, while EU formulations revenue in Q2 FY20 witnessed a growth of 21.2 percent YoY to Rs 1,401.3 crore, the release said.

Crore Yoy Revenues  crore  fy  q2  yoy  growth  rises  grow  quarter  net  rs  pharmas  total  profit  release  nearly  revenues

History of this topic

AstraZeneca Q2 net profit declines 27%, revenue up 31%
2 months ago

AstraZeneca Q2 net profit declines 27%, revenue up 31%

Live Mint  

Mumbai: AstraZeneca Pharma India Ltd posted a profit after tax of ₹38 crore, down 27% year-on-year, in the September quarter of FY25. The company’s revenue growth was driven by its portfolio of products in the oncology, biopharmaceuticals and rare disease segments, Bhavana Agrawal, chief financial officer of the company, said in a release on Wednesday. Palivizumab, also known by the …

Aurobindo Pharma Q1 Results: Net profit rises 61.3% to ₹918 crore, revenue up 10.5% YoY
5 months ago

Aurobindo Pharma Q1 Results: Net profit rises 61.3% to ₹918 crore, revenue up 10.5% YoY

Live Mint  

Aurobindo Pharma Q1 Results: Aurobindo Pharma released its April-June quarter results for fiscal 2024-25 on August 10, reporting a rise of 61.3 per cent in net profit at ₹918 crore, compared to ₹569 crore in the corresponding period last year. The pharma major's revenue from operations during the first quarter of current fiscal stood at ₹7,567 crore, registering a rise …

Stocks to watch: Ambuja Cements, Maruti, Sun Pharma, M&M, Adani Power, Infosys
5 months, 2 weeks ago

Stocks to watch: Ambuja Cements, Maruti, Sun Pharma, M&M, Adani Power, Infosys

Live Mint  

Ambuja Cements: The company reported a consolidated profit of ₹646.31 crore for Q1FY25, a 28.6% YoY decline due to rising expenses and lower revenues. Tata Steel: The company reported a 51% jump in consolidated net profit to ₹960 crore for Q1FY25, up from ₹634 crore YoY, but missed analysts’ expectations of ₹1,025 crore. Redington: The company reported a 15% YoY …

Large cap stock hits 52-week high after US FDA conducts inspection at subsidiary
1 year ago

Large cap stock hits 52-week high after US FDA conducts inspection at subsidiary

Live Mint  

Shares of Aurobindo Pharma were locked in at over four per cent upper circuit at ₹1,081.45 apiece on the BSE, hitting its new 52-week high mark on Wednesday, December 20. ‘’The US FDA had conducted an inspection at the Unit IV, a Formulation manufacturing facility, of APL Healthcare Limited, a wholly owned subsidiary of the Company, situated at Menakuru Village, …

Aurobindo Pharma share price rises more than 1% on regulatory clearance of plant
1 year, 1 month ago

Aurobindo Pharma share price rises more than 1% on regulatory clearance of plant

Live Mint  

The news on the successful Completion of US FDA Inspection at Unit I & III of Aurobindo Pharma Ltd lifted investor sentiments and the share prices gained of Aurobindo Pharma gained more than 1% in morning trades on Monday, on a day when benchmark indices were trading in red. Aurobindo Pharma in its filing on the exchanges said that United …

Aurobindo shares double on US show
1 year, 5 months ago

Aurobindo shares double on US show

Live Mint  

Aurobindo Pharma Ltd saw its stock prices more than double during the last few months, from 52-week lows of ₹397.20 on the National Stock Exchange on 3 February to 52-week highs of ₹887.70 on 14 August. The European operations, which is the second largest contributor to the company’s overall revenues and contribute more than a fourth to them, are expected …

Mankind Pharma Q1 results: Profit soars 66% on strong sales
1 year, 5 months ago

Mankind Pharma Q1 results: Profit soars 66% on strong sales

Live Mint  

Mankind Pharma Ltd on Wednesday reported a 66% growth in profit for the first quarter of fiscal year 2024 on strong domestic sales. The company's total income rose to ₹2,637 crore in June quarter of the current fiscal from ₹2,196 crore in the year-ago period, Mankind Pharma said in an exchange filing. “The pharma segment outperformed the Indian pharma market …

Aarti Drugs Q1 Results: Net profit surges 39% YoY to ₹48 crore
1 year, 5 months ago

Aarti Drugs Q1 Results: Net profit surges 39% YoY to ₹48 crore

Live Mint  

Aarti Drugs Limited released its Q1 results on Friday and reported a 38.8% surge in the net consolidated profits from ₹34.8 crore to ₹48 crore, it said in a stock regulatory filing. Among other things, the firm said that the board of directors of the company has approved buyback not exceeding 6,65,000 fully paid-up equity shares for ₹900 per equity …

Mankind Pharma Q4 results: PAT zooms 52% YoY to ₹294 Cr, revenue up 19%
1 year, 7 months ago

Mankind Pharma Q4 results: PAT zooms 52% YoY to ₹294 Cr, revenue up 19%

Live Mint  

The fourth-largest pharmaceutical company in India, Mankind Pharma, today disclosed its financial results for the fourth quarter and full year ended March 31, 2023. Mankind Pharma said its net profit for the quarter under review reached ₹294 Cr up by 52% YoY from ₹193 Cr in the corresponding quarter of the previous fiscal year. Mankind Pharma said its revenue from …

Aurobindo Pharma Q3 net drops 18% to ₹491 crore
1 year, 11 months ago

Aurobindo Pharma Q3 net drops 18% to ₹491 crore

The Hindu  

Drugmaker Aurobindo Pharma’s consolidated net profit declined more than 18%, year-on-year, in the December quarter to ₹491 crore even as revenue from operations increased 6.7% to ₹6,407.1 crore. Revenue from formulations were 9.2% more at ₹5,452.5 crore on the back of an increase in the same range in the U.S market to ₹3,001.2 crore. Vice-Chairman and MD K. Nithyananda Reddy …

Pharma stock approves interim dividend at 450%, record date next week
2 years, 7 months ago

Pharma stock approves interim dividend at 450%, record date next week

Live Mint  

While announcing its Q4FY22 earnings, drug firm Aurobindo Pharma said its board has recommended fourth interim dividend of 450% i.e ₹4.50 per equity share of Re 1/- each on the equity share capital of the company for the financial year 2021-22. The company has already fixed the record date for the purpose of payment of fourth interim dividend for the …

Bank of India, Aurobindo Pharma, Bata India: Top stocks for Investors Today
3 years, 11 months ago

Bank of India, Aurobindo Pharma, Bata India: Top stocks for Investors Today

News 18  

The stock market on Wednesday, February 10, closed in the red for the second consecutive day and witnessed volatility throughout the session. Top stocks to look for the day are: Bank of India: The public sector lender in its quarterly earnings report said that its net profit rose by 412 percent to Rs 541 crore in the December Quarter compared …

Aurobindo Pharma shares surge on Q2 earnings
4 years, 2 months ago

Aurobindo Pharma shares surge on Q2 earnings

Live Mint  

Shares of Aurobindo Pharma surged as much as 7% today after the company reported a 26% increase in consolidated net profit in the second quarter ended September. Aurobindo Pharma on Wednesday reported a 26% increase in consolidated net profit at ₹805.65 crore in the second quarter ended September. The company had posted a consolidated net profit of ₹639.53 crore in …

Aurobindo Eyes 40% Rise in US Injectables Business in FY18
7 years, 2 months ago

Aurobindo Eyes 40% Rise in US Injectables Business in FY18

Live Mint  

Aurobindo Pharma's US injectables business is expected to grow at least 40% this financial year, driven by new launches and higher sales from existing products. The company's injectables business has been growing significantly over the last two-three years, with US injectable sales rising by 67% in FY16-17 and 39% in FY15-16. The company expects about seven to nine product approvals …

Discover Related